| Donald Grewell, DO | |
|
2675 Central Ave, Billings, MT 59102-6686 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Donald Grewell |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 2675 Central Ave, Billings, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326150285 | NPI | - | NPPES |
| 0010999 | Other | MT | MDCD PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 6209 (Montana) | Primary |
| Entity Name | Yellowstone City-county Health Department |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841219698 PECOS PAC ID: 1456259159 Enrollment ID: O20031219000249 |
News Archive
American Well™ has been honored as one of the Most Innovative Companies in Healthcare by Fast Company in its annual Most Innovative Companies issue. American Well was recognized for extending Online Care to consumers and physicians nationwide in partnership with top health plans and delivery networks. Other leaders on Fast Company's list include Google, Cisco, Apple and GE, along with such rising newcomers as Twitter and Gilt Groupe.
Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald Grewell, DO Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | Donald Grewell, DO 2675 Central Ave, Billings, MT 59102-6686 Ph: (406) 238-2500 |
News Archive
American Well™ has been honored as one of the Most Innovative Companies in Healthcare by Fast Company in its annual Most Innovative Companies issue. American Well was recognized for extending Online Care to consumers and physicians nationwide in partnership with top health plans and delivery networks. Other leaders on Fast Company's list include Google, Cisco, Apple and GE, along with such rising newcomers as Twitter and Gilt Groupe.
Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.
› Verified 8 days ago
Michael D. Monday, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1775 Spring Creek Dr, Billings, MT 59102 Phone: 406-373-3500 Fax: 406-373-3520 | |
Aaron James Audet, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Angel M. Eads, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3220 Fax: 406-651-6406 | |
John Konow, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Cynthia Kay Brewer, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Amy Solomon, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Lawrence A. Hemmer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2675 Central Ave, Billings, MT 59102 Phone: 406-238-2500 |